A US company, with its origins in South Korea, is using natural killer (NK) cells to treat Alzheimer’s disease, with remarkable results.

This week, we have a conversation with Dr Paul Song, CEO of NKGen Biotech, a company with its sights set on changing the Alzheimer’s treatment landscape.

00:58-02:55: About NKGen Biotech
 02:56-05:39: Why is Alzheimer’s so challenging to treat?
 05:39-07:28: Are there other treatments making a difference?
 07:28-13:47: What is NKGen Biotech’s approach to treating Alzheimer’s?
 13:47-15:38: Can you treat multiple conditions at the same time?
 15:38-15:55: Are there any side effects?
 15:55-16:33: What dose are you able to give?
 16:33-18:31: How can you keep the cost of treatments low?
 18:31-19:19: How, and how often, will it be administered?
 19:19-20:49: How are you approaching taking on later stage Alzheimer’s?
 20:49-22:21: Are you looking to cure Alzheimer’s?
 22:21-23:50: Can this approach be used for other diseases?
 23:50-24:47: Are you looking for partnerships?
 24:47-25:47: What stage are your trials at?
 25:47-26-19: What are the next steps for NKGen Biotech?
 26:19-26:35: How are you enrolling patients?
 26:35-27:32: What is your approximate timeline?

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

Stay updated by subscribing to our newsletter